

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.usptc.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/756,899 01/09/2001 4692US Franciscus Antonius, M. Redegeld 1305 24247 09/26/2003 TRASK BRITT **EXAMINER** P.O. BOX 2550 HUYNH, PHUONG N SALT LAKE CITY, UT 84110 ART UNIT PAPER NUMBER 1644

DATE MAILED: 09/26/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

*	Application No.	Applicant(s)
Advisory Action	09/756,899	REDEGELD ET AL.
	Examiner	Art Unit
	Phuong Huynh	1644
The MAILING DATE of this communication appe		L correspondence address
THE REPLY FILED 27 August 2003 FAILS TO PLACE T Therefore, further action by the applicant is required to av final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	THIS APPLICATION IN CONDIT roid abandonment of this applica atimely filed amendment whicl	FION FOR ALLOWANCE. ation. A proper reply to a h places the application in
PERIOD FOR RE	PLY [check either a) or b)]	
 a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). 	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH	g date of the final rejection. HE FINAL REJECTION. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period o fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of t (2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any earned patent term adjustment. See 37 C	of extension and the corresponding amo the shortened statutory period for reply the later than three months after the mail	ount of the fee. The appropriate extension originally set in the final Office action; or
1.⊠ A Notice of Appeal was filed on <u>27 August 2003</u> . Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.		
2. The proposed amendment(s) will not be entered because:		
(a) 💢 they raise new issues that would require further consideration and/or search (see NOTE below);		
(b) ☑ they raise the issue of new matter (see Note below);		
(c) ☐ they are not deemed to place the application in issues for appeal; and/or	ı better form for appeal by mateı	rially reducing or simplifying the
(d) 🔲 they present additional claims without canceling a corresponding number of finally rejected claims.		
NOTE: <u>See Continuation Sheet</u> .		
3. Applicant's reply has overcome the following rejection(s):		
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).		
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:		
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	use it is not directed SOLELY to	issues which were newly
7. For purposes of Appeal, the proposed amendment(explanation of how the new or amended claims wo	, , ,	
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed: None.		
Claim(s) objected to: None.		
Claim(s) rejected: <u>1-5,10-13,16-25,31 and 32</u> .		
Claim(s) withdrawn from consideration: None.		
8. The proposed drawing correction filed on is a	a)☐ approved or b)☐ disappr	oved by the Examiner.
9. Note the attached Information Disclosure Statement	t(s)(PTO-1449) Paper No(s)	
10. Other:		
		
		İ

Continuation of 2. NOTE: The proposed amendment to claim 10 "8 micrograms per Liter" and claim 1 "diluent" raises the issue of new matter because said phrase has no clear support in the specification or claims as originally filed. Applicants have not pointed out the support for said phrases. Further, it is not clear which disease state the claimed pharmaceutical composition intends to treat.

CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600